本帖最后由 老马 于 2012-1-13 21:20 编辑 ! i& {* d! j, D$ A" [0 _. M) Z
! d3 i9 i9 N0 f7 i8 A3 p% t- T5 p
爱必妥和阿瓦斯丁的比较& f- j2 C \. Z' W3 k+ J
: p5 x5 d. f# P0 n1 z: lhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
+ k, ~' B _6 x% ]# D1 S
+ D& r5 N! P8 ~
; d6 b# O" S2 {+ uhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/( q- d7 U0 m- U
==================================================0 j7 {% L5 v, N) E6 y4 ]4 u# W5 v
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)( r, G6 M0 K0 k# r( {7 G6 x; x
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.1 D2 c' s \$ O9 j2 U, K
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.! l2 Q# m: c: r3 O* a" Z
|